1 |
Nicoli F, Gallerani E, Sicurella M, Pacifico S, Cafaro A, Ensoli B, Marconi P, Caputo A, Gavioli R. The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. Vaccines (Basel) 2020;8:E274. [PMID: 32512757 DOI: 10.3390/vaccines8020274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Nicoli F, Gallerani E, Sforza F, Finessi V, Chachage M, Geldmacher C, Cafaro A, Ensoli B, Caputo A, Gavioli R. The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells. AIDS 2018;32:575-81. [PMID: 29280760 DOI: 10.1097/QAD.0000000000001734] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
3 |
Nicoli F, Chachage M, Clowes P, Bauer A, Kowour D, Ensoli B, Cafaro A, Maboko L, Hoelscher M, Gavioli R, Saathoff E, Geldmacher C. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. BMC Infect Dis 2016;16:344. [PMID: 27450538 DOI: 10.1186/s12879-016-1647-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
4 |
Schulze Zur Wiesch J, Beisel C. The elephant and the blind men: making sense of the seemingly multifaceted role of Blimp-1 in HIV-1 infection. AIDS 2015;29:134-6. [PMID: 25562500 DOI: 10.1097/QAD.0000000000000513] [Reference Citation Analysis]
|